Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Subcutaneous Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma from EPCORE NHL-5

Irit Avivi Mazza, Won Seog Kim, Po-Shen Ko, Carlos Grande, David Lavie, David Chism, Mostafa Seliem, Edwin E. Jeng, Neha Joshi, Satya Siddani, Wissam Assaily, Mariana Sacchi, Minh Dinh, Abraham Avigdor

Blood (2023) 142 (Supplement 1): 438.

https://doi.org/10.1182/blood-2023-180089

Published: 2023

Journal Articles

Identification of Optimal Dosing Regimen for Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Tommy Li, Leonid Gibiansky, Apurvasena Parikh, Christopher W. Chiu, Mariana Sacchi, Huaibao Feng, Tahi Ahmadi, Manish Gupta, Steven Xu

Blood (2023) 142 (Supplement 1): 3135.

https://doi.org/10.1182/blood-2023-181322

Published: 2023

Journal Articles

Population Pharmacokinetics of Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Tommy Li, Leonid Gibiansky, Apurvasena Parikh, Marcel van der Linden, Kinjal Sanghavi, Matthew Putnins, Mariana Sacchi, Huaibao Feng, Tahamtan Ahmadi, Manish Gupta, Steven Xu

Blood (2023) 142 (Supplement 1): 4481.

https://doi.org/10.1182/blood-2023-179555

Published: 2023

Journal Articles

Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults

Paul Harker-Murray, Christine Mauz-Körholz, Thierry Leblanc, Maurizio Mascarin, Gérard Michel, Stacy Cooper, Auke Beishuizen, Kasey J. Leger, Loredana Amoroso, Salvatore Buffardi, Charlotte Rigaud, Bradford S. Hoppe, Julie Lisano, Stephen Francis, Mariana Sacchi, Peter D. Cole, Richard A. Drachtman, Kara M. Kelly, Stephen Daw

Blood (2023) 141 (17): 2075–2084.

https://doi.org/10.1182/blood.2022017118

Published: 2023

Includes: Supplemental data

Journal Articles

Improvements in Lymphoma Symptoms and Health-Related Quality of Life in Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Subcutaneous Epcoritamab (EPCORE NHL-1)

Tycel Phillips, Pieternella Lugtenburg, Anupama Kalsekar, Alex Mutebi, Anthony Wang, Julie Blaedel, Katherine Kosa, Susan Martin, Mariana Sacchi, Catherine Thieblemont

Blood (2022) 140 (Supplement 1): 8022–8023.

https://doi.org/10.1182/blood-2022-159544

Published: 2022

Journal Articles

Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood (2022) 140 (Supplement 1): 9443–9445.

https://doi.org/10.1182/blood-2022-158245

Published: 2022

Journal Articles

Real-World Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Standard of Care: A Cota Database Analysis

Andrew Ip, Alex Mutebi, Tongsheng Wang, Monika P. Jun, Anupama Kalsekar, Fernando Rivas Navarro, Anthony Wang, Rajesh Kamalakar, Mariana Sacchi, Brian Elliott

Blood (2022) 140 (Supplement 1): 6693–6694.

https://doi.org/10.1182/blood-2022-159569

Published: 2022

Journal Articles

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results

Ranjana H. Advani, Alison J. Moskowitz, Nancy L. Bartlett, Julie M. Vose, Radhakrishnan Ramchandren, Tatyana A. Feldman, Ann S. LaCasce, Beth A. Christian, Stephen M. Ansell, Craig H. Moskowitz, Lisa Brown, Chiyu Zhang, David Taft, Sahar Ansari, Mariana Sacchi, Linda Ho, Alex F. Herrera

Blood (2021) 138 (6): 427–438.

https://doi.org/10.1182/blood.2020009178

Published: 2021

Includes: Supplemental data

Journal Articles

Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients

Christopher A. Yasenchak, MD, Rodolfo Bordoni, MD, Dipti Patel-Donnelly, MD, Timothy Larson, MD, Jerome Goldschmidt, MD, Ralph V. Boccia, MD, Vivian J.M. Cline, Mariana Sacchi, MD, Andres Forero-Torres, Robert B. Sims, MD, Jingmin Liu, Jonathan W. Friedberg, MD MSSc

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136583

Published: 2020

Journal Articles

Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Mediastinal Gray Zone Lymphoma: Primary Efficacy and Safety Analysis of the Phase 2 CheckMate 436 Study

Armando Santoro, Alison J. Moskowitz, MD, Silvia Ferrari, MD, Carmelo Carlo-Stella, MD, Michelle A. Fanale, MD, Stephen Francis, Mariana Sacchi, MD, Kerry J. Savage, MDMSc

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-137653

Published: 2020

Journal Articles

Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study

Alison J. Moskowitz, MD, Ranjana H Advani, MD, Nancy L. Bartlett, MD, Julie M Vose, MDMBA, Radhakrishnan Ramchandren, MD, Tatyana A. Feldman, MD, Ann S. LaCasce, MD MMSc, Beth A. Christian, MD, Stephen M Ansell, MD PhD, Craig H. Moskowitz, Lisa Brown, David Taft, Sahar Ansari, Daniel E. Zak, PhD, Mariana Sacchi, MD, Thomas Manley, MD, Alex F. Herrera, MD

Blood (2019) 134 (Supplement_1): 238.

https://doi.org/10.1182/blood-2019-122576

Published: 2019

Journal Articles

Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing)

Ranjana H. Advani, MD, Alison J. Moskowitz, MD, Nancy L. Bartlett, MD, Julie M. Vose, MDMBA, Radhakrishnan Ramchandren, MD, Tatyana A. Feldman, MD, Ann S. LaCasce, MD MSc, Beth A. Christian, MD, Stephen M. Ansell, MD PhD, Craig H. Moskowitz, MD, Keenan Fenton, Carol Anne Ogden, PhD, David Taft, Daniel E. Zak, PhD, Mariana Sacchi, MD, Faith Galderisi, DO, Alex F. Herrera, MD

Blood (2018) 132 (Supplement 1): 1635.

https://doi.org/10.1182/blood-2018-99-110002

Published: 2018

Journal Articles

Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma

Paul Harker-Murray, MD PhD, Thierry Leblanc, MD, Maurizio Mascarin, Christine Mauz-Körholz, Gerard Michel, MD, Stacy Cooper, MD, Auke Beishuizen, MD PhD, Kasey J. Leger, MD MSc, Alberto Garaventa, Salvatore Buffardi, MD, Laurence Brugieres, MD, Kara M. Kelly, MD, Peter D. Cole, MD, Richard A. Drachtman, Faith Galderisi, DO, Mariana Sacchi, MD, Ying-Ming Jou, Stephen Daw

Blood (2018) 132 (Supplement 1): 927.

https://doi.org/10.1182/blood-2018-99-111279

Published: 2018

Journal Articles

Baseline Tumor Transcriptome Characteristics Associated with the Response of Relapsed/Refractory Hodgkin Lymphoma Patients to Brentuximab Vedotin in Combination with Nivolumab

Daniel E. Zak, PhD, Carol Anne Anne Ogden, PhD, Alex F. Herrera, MD, Mariana Sacchi, MD, Matt Onsum, PhD

Blood (2018) 132 (Supplement 1): 2837.

https://doi.org/10.1182/blood-2018-99-115481

Published: 2018

Journal Articles

Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study

Jonathon B. Cohen, MDMS, John Kuruvilla, MD, Andreas Engert, MD, Stephen M. Ansell, MD PhD, Anas Younes, MD, Hun Ju Lee, MD, Marek Trněný, Kerry J Savage, BSc, MD MSc, Radhakrishnan Ramchandren, MD, Graham P. Collins, MB BS DPhil, Pier Luigi Zinzani, MD, Jan Paul De Boer, MD PhD, Margaret A. Shipp, MD, Armando Santoro, MD, John M. Timmerman, MD, Mariana Sacchi, MD, Oumar Sy, PhD, Philippe Armand, MD PhD

Blood (2018) 132 (Supplement 1): 2932.

https://doi.org/10.1182/blood-2018-99-114502

Published: 2018

Journal Articles

Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study

Philippe Armand, MD PhD, Andreas Engert, MD, Anas Younes, MD, Hun Ju Lee, MD, Armando Santoro, MD, Pier Luigi Zinzani, MD, John M. Timmerman, MD, Graham P. Collins, MB BS DPhil, Radhakrishnan Ramchandren, MD, Jonathon B. Cohen, MD MS, Jan Paul De Boer, MD PhD, Kerry J Savage, BSc, MD MSc, John Kuruvilla, MD, Marek Trněný, Margaret A. Shipp, MD, Mariana Sacchi, MD, Anne Sumbul, MS, Stephen M. Ansell, MD PhD

Blood (2018) 132 (Supplement 1): 2897.

https://doi.org/10.1182/blood-2018-99-112067

Published: 2018

Journal Articles

Effect of Nivolumab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma after Autologous Transplantation: Results from the Multicohort Phase 2 Checkmate 205 Study

Andreas Engert, MD, Fiona Taylor, Bryan Bennett, Clara Chen, PhD BS, MS, Kim Cocks, Jeffrey McDonald, Erin Mann, Mariana Sacchi, David Cella, PhD

Blood (2017) 130 (Supplement 1): 3441.

https://doi.org/10.1182/blood.V130.Suppl_1.3441.3441

Published: 2017

Journal Articles

Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 Checkmate 205 Study

Jonathon B Cohen, MDMS, Andreas Engert, MD, Stephen M Ansell, MD PhD, Anas Younes, MD, Marek Trneny, MD, Kerry J Savage, BSc, MD MSc, Radhakrishnan Ramchandren, MD, Graham Collins, MD PhD, Michelle A. Fanale, MD, Philippe Armand, MD PhD, Pier Luigi Zinzani, MD PhD, Jan Paul De Boer, MD PhD, Margaret A. Shipp, MD, Armando Santoro, MD, John M Timmerman, MD, Mariana Sacchi, Oumar Sy, PhD, John Kuruvilla, MD

Blood (2017) 130 (Supplement 1): 650.

https://doi.org/10.1182/blood.V130.Suppl_1.650.650

Published: 2017

Journal Articles

Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study

Radhakrishnan Ramchandren, MD, Michelle A. Fanale, MD, Antonio Rueda, Philippe Armand, MD PhD, Marek Trněný, MD PhD, Tatyana A Feldman, MD, Stephen M Ansell, MD PhD, Mariano Provencio, MD, Ulrich Jaeger, MD, Jonathon B Cohen, MDMS, Kerry J Savage, BSc, MD MSc, Wolfgang Willenbacher, Mariana Sacchi, Anne Sumbul, Eva Domingo Domenech, MD

Blood (2017) 130 (Supplement 1): 651.

https://doi.org/10.1182/blood.V130.Suppl_1.651.651

Published: 2017

Journal Articles

Expression of Major Histocompatibility Complex (MHC) Class II, but Not MHC Class I, Predicts Outcome in Patients with Classical Hodgkin Lymphoma (cHL) Treated with Nivolumab (Programmed Death-1 [PD-1] Blockade)

Blood (2017) 130 (Supplement 1): 1450.

https://doi.org/10.1182/blood.V130.Suppl_1.1450.1450

Published: 2017

NARROW

Subcutaneous Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma from EPCORE NHL-5

Identification of Optimal Dosing Regimen for Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Population Pharmacokinetics of Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults

Improvements in Lymphoma Symptoms and Health-Related Quality of Life in Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Subcutaneous Epcoritamab (EPCORE NHL-1)

Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Real-World Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Standard of Care: A Cota Database Analysis

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results

Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients

Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Mediastinal Gray Zone Lymphoma: Primary Efficacy and Safety Analysis of the Phase 2 CheckMate 436 Study

Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study

Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing)

Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma

Baseline Tumor Transcriptome Characteristics Associated with the Response of Relapsed/Refractory Hodgkin Lymphoma Patients to Brentuximab Vedotin in Combination with Nivolumab

Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study

Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study

Effect of Nivolumab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma after Autologous Transplantation: Results from the Multicohort Phase 2 Checkmate 205 Study

Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 Checkmate 205 Study

Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study

Expression of Major Histocompatibility Complex (MHC) Class II, but Not MHC Class I, Predicts Outcome in Patients with Classical Hodgkin Lymphoma (cHL) Treated with Nivolumab (Programmed Death-1 [PD-1] Blockade)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only